Treatment with the monoclonal calcitonin gene‐related peptide receptor antibody erenumab: A real‐life study

Background and purpose New prophylactics for migraine, targeting calcitonin gene‐related peptide (CGRP), have recently emerged. Real‐world data are important for a comprehensive understanding of treatment response. We assessed the consistency of response to erenumab, a monoclonal CGRP receptor antibody, in a real‐world setting, in order to determine which patients may be considered responders in clinical practice. Methods All erenumab‐treated...